GlassScriptPhysician profile
Wendy C Bennett
NPI 1295143980
$4,136.51
in general payments reported to CMS, 2019-2025
27 companies · $819 in 2025
The $819 reported for 2025 was more than what 94% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $951 · 2023: $799 · 2024: $910 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.45 |
| Education | $152.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $687.62 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $640.37 | 2021-2025 | |
| Biogen, INC. | $322.16 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $317.41 | 2021-2025 | |
| Evofem Biosciences, INC. | $267.95 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $249.43 | 2021-2025 | |
| Pfizer INC. | $223.12 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $203.63 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $185.93 | 2021-2022 | |
| Organon LLC | $169.71 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $136.37 | 2023-2025 | Accrufer |
| Myriad Women'S Health, INC. | $117.99 | 2023 | Myrisk |
| Millicent US INC | $96.00 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Hologic Sales and Service, LLC | $93.19 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $85.23 | 2023-2024 | Prolia, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $76.39 | 2021-2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $61.74 | 2021-2022 | |
| Ethicon US, LLC | $48.32 | 2021-2022 | |
| Agile Therapeutics, INC. | $23.35 | 2021 | |
| Teleflex LLC | $20.63 | 2025 | Kmedic |
| Smith+Nephew, INC. | $19.11 | 2025 | Stravix |
| Urovant Sciences INC | $18.60 | 2021 | |
| Exeltis, USA INC. | $17.50 | 2025 | Slynd |
| Therapeuticsmd, INC. | $15.55 | 2022 | |
| Novo Nordisk INC | $13.36 | 2023 | Saxenda, Wegovy |
| Scynexis, INC. | $13.17 | 2022 | |
| Kci USA, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.